Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXV-802 and EXV-801 in Alzheimer's Disease Agitation
NCT07284472Phase 3Recruiting
- Sponsor
- Exciva
- Start
- Feb 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of EXV-802, deramciclane in agitation, sponsored by Exciva. Started Feb 2026; status: recruiting.
02
Drugs
EXV-802deramciclane
03
Conditions
agitation
Beyond the preview
Go deeper on NCT07284472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284472.